1	
2	
3	
4	Application of observational research methods to real-world
5	studies for rare disease drugs: a scoping review protocol
6	
7	Yuti P Patel ¹ , Lea Ghaddar ¹ , Yuqi Lin ¹ , Nuzat Karim ¹ , Kelvin Chan ^{2,3} , Lee Dupuis ^{1,4} , Mina
8	Tadrous ^{1*}
9	
10	
11	
12	
13	
14	1. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
15	2. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
16 17 18	 Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
19	4. The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
20	
21 22	*Corresponding Author:
23	Mina Tadrous
24	144 College St.
25	Toronto, Ontario
26 27	mina.tadrous(@utoronto.ca
28 29	Word count: 3070
30	Abstract word count: 292

31 Abstract

32 Objective: The primary objective is to identify which observational research methods have been 33 used in the last 5 years in rare disease drug evaluation and how they are applied to generate 34 adequate evidence regarding the real-world effectiveness or safety of rare disease drugs.

35

Background: Rare disease is an umbrella term for a condition which affects <200,000 people 36 37 each year and despite the rarity of these conditions, collectively they encompass approximately 38 7000 different conditions. With the striking number of rare conditions, many pharmaceutical 39 manufacturers are introducing an increased number of drugs to treat them. However, due to small 40 patient populations, heterogeneity and other factors related to rare diseases, there are feasibility 41 concerns regarding the generation of adequate efficacy and safety evidence using conventional 42 randomized controlled trials (RCTs). Recently, real-world evidence generated through observational (or real-world) studies has been proposed to address some of the feasibility 43 44 concerns with RCTs by measuring drug effectiveness or safety in the real-world setting. 45 However, there remain methodological concerns due to a lack of randomization/masking. This proposed scoping review aims to identify which observational research methods in the last 5 46 years are used in rare disease drug evaluation to address methodological concerns and how 47 48 they're applied to generate evidence on drug effectiveness or safety.

49

50 Inclusion criteria: Articles must be primary observational or real-world studies reporting rare 51 disease drug effectiveness or safety published between 2018-2023. Literature reviews, meta-52 analyses, randomized control trials, case series, case reports, opinion pieces, conference 53 abstracts, and studies with unavailable full-text articles will be excluded.

54	Methods: The search strategy will combine the following key search concepts: rare disease	
55	drugs for rare disease and observational/real-world studies. The search will be conducted in	
56	MEDLINE and EMBASE.	
57		
58	Review registration number: Open Science Framework, <u>https://osf.io/f3wpv</u>	
59		
60	Keywords: Rare disease drug, Observational research methods, real-world studies	
61		

62 Introduction

63 A rare disease, also referred to as an orphan disease, is a medical condition that affects a small proportion of the population. Currently, an international consensus on the definition of a rare 64 65 disease does not exist. For example, in Canada and the European Union, a rare disease is defined 66 as a condition that affects fewer than 1 in 2,000 people, while in the United States, it is considered rare if it affects fewer than 200,000 people. By these definitions, approximately 7,000 different 67 68 conditions qualify as rare diseases, resulting in upwards of 300 million people worldwide being 69 affected(1-4). With a striking number of rare diseases and people affected, the USA and European 70 Commissions implemented the Orphan Drug Act (ODA) in 1983, and Orphan Medicinal Products 71 (OMP) in 2000 to incentivize pharmaceutical manufacturers to develop drugs for rare diseases 72 (3,5,6). Despite orphan drug incentives being in place for many decades, it is in recent years that an increasing number of drugs for treating rare diseases have been developed. Orphan drug 73 74 approvals increased from 14 in 2000 to 77 in 2017, and as of recently in 2022, nearly half of all 75 new drug approvals by the FDA were for a rare condition(7).

76 With respect to drug evaluation, there are data and statistical constraints to generating adequate 77 evidence on the benefits of a therapy for treating a rare disease.(1) From the perspective of drug 78 regulatory and health technology assessment bodies, randomized controlled trials (RCT) are the 79 "gold standard" to evaluate the efficacy and safety of a drug in a particular patient population (8,9). 80 RCTs are typically designed prospectively, double blinded and randomized, providing equal 81 chance for all patients being allocated to the active treatment or comparator and reduces the extent 82 of bias(9). The controlled environment of an RCT allows for hypotheses to be tested, though, 83 results from the RCT can only be extrapolated to patients represented in the trial; thus, there are 84 limitations regarding generalizability of results(8). Additionally, statistical analysis plans for RCTs

require an adequate number of patients to statistically power the study(8). Given the nature of rare
diseases, conventional drug evaluations such as RCTs are most often not feasible due to the small
patient populations and heterogeneity in the manifestation of the rare disease. These challenges
are not unique to rare diseases; however, the limited number of patients amplifies these challenges
and presents methodological challenges (1,10).

90 Given the difficulties in conducting RCT for rare diseases, Real-World Evidence (RWE) has 91 emerged as a viable solution for producing clinical evidence related to the utilization, as well as 92 the potential advantages or risks of a treatment, derived from an analysis of real-world data 93 (RWD)(11,12). Based on the FDA definition, RWD is "data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources" and can be collected 94 95 prospectively/retrospectively through observational studies to generate RWE(11,12). 96 Observational studies such as cohort, case-control, and cross-sectional designs have a well-97 established history of use in drug research. They contribute valuable insights into real-world drug 98 effectiveness or safety, drug utilization patterns, serve to augment the outcomes of RCTs and 99 overall complement the findings of an RCT to provide a more comprehensive view of a drug's 100 performance(1,10,11). In the specific context of rare disease drug evaluation, RWE obtained from 101 observational studies has the potential to address issues associated with limited sample sizes and 102 the generalizability concerns. However, given the absence of randomization and blinding in 103 observational studies, there are methodological concerns regarding the validity of results due to 104 the potential presence of confounding or selection bias(1,10). While there have been research 105 methods introduced to address these issues, there remains a lack of consistency in their application 106 with respect to rare disease drug evaluation and ultimately the quality of RWE for decision-107 making. With the widespread adoption of RWE in rare disease drug research, regulatory decision-

108 making, and drug policy over the past 5 years, it is imperative to understand how established observational research methodologies have been incorporated to address methodological 109 110 challenges such as the presence of confounders and small patient populations. This understanding 111 will aid in informing the appropriate and consistent application of observational research methods 112 to adequately generate RWE for rare disease drugs moving forward. To address this knowledge 113 gap, the proposed scoping review aims to identify in the last 5 years, which observational research methods are being utilized in rare disease RWE drug evaluation and how they're applied to 114 generate adequate evidence regarding the real-world effectiveness or safety. 115

- **116 Review Questions**
- 117 In the last 5 years, how have observational research methods been used in the generation of

118 RWE on the safety or effectiveness of drugs used to treat rare disease?

- a) Which research methods are being utilized to account for potential confounders or small
 sample sizes in observational research/studies for rare disease drug research?
- b) How are the research methods identified being applied to generate drug safety or
- 122 effectiveness in the real-world setting?
- 123 c) Which rare diseases are being studied in observational research/studies in the last 5124 years?

125 Inclusion Criteria

126 **Participants**

127 This review will focus on rare diseases, drugs for rare disease, orphan diseases, and orphan disease

128 drugs. Rare disease will be defined in accordance with Health Canada, as a condition that affects

129 fewer than 1 in 2,000 people (13).

130 Concept

131 This proposed scoping review will consider observational research on rare disease drug132 effectiveness and/or safety.

133 Context

This review will examine studies using health administrative data from all healthcare settings andregions in the last 5-years.

136 Types of sources

For this scoping review, published and unpublished observational studies (i.e. cohort, case-control
and cross-sectional designs) also referred to as real-world studies, between 2018- 2023 will be
included.

140

141 Exclusion Criteria

Studies that do not evaluate an intervention to treat a rare disease based on the definition above; do not use health administrative data; published on or before Dec 31, 2017 in a language other than English; literature reviews (i.e. systematic, scoping, narrative, etc.), meta-analyses, randomized control trials, case series and case reports, study protocols, opinion pieces (i.e. editorials, commentaries, letters, etc.), conference abstracts, and studies with unavailable full-text articles will be excluded.

149 Methods

150 Information Sources

A structured search will be conducted in MEDLINE and EMBASE. A supplementary search of reference lists of included articles and relevant literature searches will be conducted to identify any additional relevant articles that may have been missed by the search strategy. Reporting will be done in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) reporting guidelines.(14)

156

157 Search Strategy

158 To initiate the search strategy, a preliminary limited search of MEDLINE was undertaken to 159 identify relevant articles on the topic. The preliminary search indicated the selection of the 160 following key search concepts: rare diseases/ rare disease drugs and observational/real-world 161 studies used in the search strategy. During the preliminary search, it was found that terms like realworld evidence, real-world data, and real-world studies were used interchangeably with 162 163 established terms like observational studies/observational research. To ensure a comprehensive 164 search study, these concepts were treated as synonyms in this review. Moreover, to ensure the 165 relevance and timeliness of this review, a 5-year timeframe was integrated into this scoping review, considering the recent issuance of RWE guidance documents by various agencies(15). Upon the 166 selection of the search concepts, the titles and abstracts of relevant articles were scanned to select 167 subject headings and text words used to develop the search strategy for MEDLINE (see Appendix 168 169 1). The subject headings, text words and keyword queries as well as other database specific syntax 170 will be adapted for EMBASE.

172 Study Records

173 Data Management

After conducting searches in both MEDLINE and EMBASE, all identified citations will be transferred to Covidence Systematic Review Software (Veritas Health Innovation in Melbourne, Australia), for screening. To eliminate duplicate citations, we will employ the Bramer deduplication method(16). The study selection process will be facilitated through the Covidence Systematic Review Software. Additionally, the data collection process will be managed using Microsoft Excel.

180

181 Selection Process

182 Title and Abstract Screening

183 To ensure accuracy and consistency in the screening process, two independent reviewers will screen the titles and abstracts of a test set of articles based on the inclusion criteria. Titles and 184 185 abstracts of articles that do not meet the inclusion criteria will be excluded, and any disagreements 186 or potential modifications to the eligibility criteria will be deliberated by the reviewers. The 187 interrater agreement between the two independent reviewers will be computed using Microsoft 188 Excel and if 80% agreement is obtained between the two reviewers, the remaining articles will be 189 screened independently by the two reviewers. If the agreement percentage falls below 80%, the study team will review and refine the criteria as well as retrain screeners, as necessary(17). They 190 will then conduct a second round of screening with a new subset of articles until a satisfactory 191 192 level of agreement is attained. The full-text for articles that potentially meet the criteria will be 193 downloaded and imported into Covidence Systematic Review Software for full-text screening.

194 Full-text Screening

195 The full texts of the articles that successfully passed the screening will undergo a comprehensive 196 evaluation against the inclusion criteria, conducted by two independent reviewers. If any article is 197 found not to meet the inclusion criteria, the rationale for its exclusion will be documented. Any 198 discrepancies between the reviewers will be addressed through discussion and resolved with the 199 input of a third reviewer. The outcomes of the search and study selection process will be outlined in the final scoping review using a flow diagram in accordance with the Preferred Reporting Items 200 201 for Systematic Reviews and Meta-analyses extension for scoping review (PRISMA-ScR) 202 guidelines(14).

203 Data Extraction

Using Microsoft Excel, a data extraction form will be created to record necessary information from all included articles. Prior to the actual data extraction, both reviewers will test the data extraction form on a subset of articles to ensure consistent and accurate data retrieval. Once a consensus is established, both reviewers will independently extract data from the remaining articles within the same set of included articles. To maintain consistency, a third reviewer will perform random spot checks on 5% of the included articles.

210

The extracted data variables will include general article characteristics (i.e., year, authors, journal, etc.), study design, rare disease studied, rare disease drug studied and its characteristics (i.e., formulation, drug class), data sources, observational research methods undertaken including the authors' rationale for the choice of methods, outcomes including how they were defined and measured, key findings, conclusions, and funding sources(ie. industry, academic, government etc). A draft extraction tool is provided (see Appendix 2). If required, the data extraction tool will be

iteratively modified as necessary early during the extraction process, and modification will be detailed in the final scoping review. Any disagreements between the two reviewers will be resolved through discussion with a third reviewer. With respect to missing data, the authors of the paper will be contacted and requested to provide additional information. In cases where the data cannot be obtained, the absence of that information will be documented as 'unreported.'

222 Data Analysis and Presentation

223 A descriptive quantitative analysis of the included articles will be conducted using Microsoft 224 Excel, alongside a qualitative analysis of appropriate variables as captured in the extraction tool. 225 Data for the first review question will quantify the frequency of each observational research 226 method discussed in the included studies. Data for the second review question will reflect the 227 frequency counts regarding the rationale of method selection and how its application addressed the methodological concerns with the rare disease being studied. Data for the third review question 228 229 will quantify the frequency of each rare disease discussed in the included studies. The outcomes 230 of the search and the process of including studies will be visually represented in a PRISMA flow 231 diagram as per reference(14). The relevant data gathered during the extraction will be illustrated 232 in suitable tables and figures, serving to highlight the current evidence and knowledge gaps in literature. A descriptive summary of how observational research methods included in the review 233 234 were applied to generate the health outcomes of interest will be included with the tabular results. 235 The findings from this scoping review will support researchers in understanding which 236 observational research methods can be applied to certain rare disease drug studies to overcome 237 methodological challenges to obtain RWE on drug effectiveness or safety.

Reference: 238

- Gagne JJ, Thompson L, O'Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014 Nov 24;349(nov24 15):g6802–g6802.
- Yates N, Hinkel J. The economics of moonshots: Value in rare disease drug development.
 Clin Transl Sci. 2022 Apr 25;15(4):809–12.
- 3. Groft SC, Posada M, Taruscio D. Progress, challenges and global approaches to rare diseases. Acta Paediatr. 2021 Oct 19;110(10):2711-6.
- 4. Gupta S. Rare diseases: Canada's 'research orphans'. Open Med. 2012;6(1):e23-7.
- Herder M. What Is the Purpose of the Orphan Drug Act? PLoS Med. 2017 Jan 3;14(1):e1002191.
- European Parliament and of the Council. Regulation (EC) No 141/2000 of the European
 Parliament and of the Council of 16 December 1999 on orphan medicinal products.
 Brussels; 2000 [Internet]. [cited 2023 Nov 11]. Available from: https://eur-
- 252 lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141
- Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions
 targeted by orphan drug designations and approvals over the forty years of the Orphan
 Drug Act. Orphanet J Rare Dis. 2023 Jun 23;18(1):163.
- 8. Suvarna V. Real world evidence (RWE) Are we (RWE) ready? Perspect Clin Res.
 2018;9(2):61.
- 9. Abrahamyan L, Feldman BM, Tomlinson G, Faughnan ME, Johnson SR, Diamond IR, et
 al. Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med
 Genet. 2016 Dec 14;172(4):313–31.
- 261 10. Whicher D, Philbin S, Aronson N. An overview of the impact of rare disease
 262 characteristics on research methodology. Orphanet J Rare Dis. 2018 Dec 19;13(1):14.
- Wu J, Wang C, Toh S, Pisa FE, Bauer L. Use of real-world evidence in regulatory
 decisions for rare diseases in the United States—Current status and future directions.
 Pharmacoepidemiol Drug Saf. 2020 Oct 30;29(10):1213–8.
- Liu J, Barrett JS, Leonardi ET, Lee L, Roychoudhury S, Chen Y, et al. Natural History
 and Real-World Data in Rare Diseases: Applications, Limitations, and Future
 Perspectives. The Journal of Clinical Pharmacology. 2022 Dec 3;62(S2).
- 269 13. Government of Canada- Health Canada. Building a National Strategy for High-Cost Drugs
 270 for Rare Diseases: A Discussion Paper for Engaging Canadians. 2021.
- 14. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018 Oct 2;169(7):467–73.
- The Canadian Agency for Drugs and Technologies in Health. Guidance for Reporting
 Real-World Evidence . 2023.
- Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database
 search results for systematic reviews in EndNote. J Med Libr Assoc. 2016 Jul;104(3):240–
 3.
- 279 17. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb).
 280 2012;22(3):276–82.
- 281
- 282

283 Appendix 1: Search Strategy

284 MEDLINE

285 Search conducted on Oct 31, 2023

1	exp Rare Diseases/	14098
2	exp Orphan Drug Production/	1483
3	((rare or orphan) adj2 disease*).tw,kf.	49303
4	((rare or orphan) adj2 drug*).tw,kf.	2751
5	or/1-4 [**rare disease]	60722
6	exp Observational Studies as Topic/	9100
7	exp Retrospective Studies/	1152042
8	((observational adj2 stud*) or research).tw,kf.	2311724
9	or/6-8 [**Observational research]	3381917
10	real-world evidence.mp.	4876
11	real-world data.mp.	10904
12	real-world stud*.mp.	4475
13	or/10-12 [**real-world studies]	18495
14	9 or 13	3392850
15	5 and 14	8716
16	limit 15 to yr="2018 -Current"	4645

286

287 EMBASE

288 Search conducted on Oct 31, 2023

1	exp Rare Diseases/	50479
2	exp Orphan Drug Production/	3910
3	((rare or orphan) adj2 disease*).tw,kf.	80088
4	((rare or orphan) adj2 drug*).tw,kf.	5308
5	or/1-4 [**rare disease]	112389
6	exp Observational Studies as Topic/	342056
7	exp Retrospective Studies/	1512126
8	((observational adj2 stud*) or research).tw,kf.	3041887
9	or/6-8 [**Observational research]	4490980
10	real-world evidence.mp.	9260
11	real-world data.mp.	21416
12	real-world stud*.mp.	8584
13	or/10-12 [**real-world studies]	36056
14	9 or 13	4508418

15	5 and 14	16656
16	limit 15 to yr="2018 -Current"	9590

Appendix 2: Data Extraction Form

General article information		
Title		
First Authors		
Journal		
Year		
DOI		
Country(s)		
Continent		
Funding source(s)		
Study overview		
Study design		
Rare disease being studied		
Rare disease intervention being used		
Characteristics of the intervention		
Primary study aim/objective		
Data sources		
Data sources used		
Healthcare setting		
Methodology		
Observational research method(s) used		
Authors' rationale for use of the method(s)		
Outcomes		
Outcomes being measured		
How are the outcomes defined		
How are the outcomes measured		
Results		
Summary of key findings		
Conclusions		